sorafenib has been researched along with abt-199 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (abt-199) | Trials (abt-199) | Recent Studies (post-2010) (abt-199) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,483 | 150 | 1,469 |
| Protein | Taxonomy | sorafenib (IC50) | abt-199 (IC50) |
|---|---|---|---|
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0392 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0667 | |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | 0.0044 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 1.445 | |
| Bcl-2-related protein A1 | Homo sapiens (human) | 0.0044 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentzen, SM; Civin, CI; Emadi, A; Fox, JM; Kim, M; Kingsbury, TJ; Lapidus, RG; McCullough, S; Moses, BS; Mott, BT; Rudek, MA; Tyner, JW | 1 |
| Duffield, A; Hu, Y; Levis, M; Li, L; Nguyen, B; Seale, T; Seo, J; Small, D; Wu, M; Zhu, R | 1 |
| Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS | 1 |
3 other study(ies) available for sorafenib and abt-199
| Article | Year |
|---|---|
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.
Topics: Artemisinins; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Humans; Sorafenib; Sulfonamides | 2021 |
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Topics: Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Sulfonamides; THP-1 Cells | 2021 |
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2022 |